Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

STAMP inhibitor

DRUG CLASS:

STAMP inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	asciminib Sensitive: A1 - Approval asciminib Sensitive : A1	asciminib Sensitive: A1 - Approval asciminib Sensitive : A1
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	asciminib Sensitive: A1 - Approval asciminib Sensitive : A1	asciminib Sensitive: A1 - Approval asciminib Sensitive : A1
BCR-ABL1 P465S	Chronic Myeloid Leukemia	BCR-ABL1 P465S	Chronic Myeloid Leukemia	asciminib Resistant: A2 - Guideline asciminib Resistant : A2	asciminib Resistant: A2 - Guideline asciminib Resistant : A2
BCR-ABL1 A337T	Chronic Myeloid Leukemia	BCR-ABL1 A337T	Chronic Myeloid Leukemia	asciminib Resistant: A2 - Guideline asciminib Resistant : A2	asciminib Resistant: A2 - Guideline asciminib Resistant : A2
BCR-ABL1 fusion	Acute Myelogenous Leukemia	BCR-ABL1 fusion	Acute Myelogenous Leukemia	asciminib Sensitive: C1 - Off-label asciminib Sensitive : C1	asciminib Sensitive: C1 - Off-label asciminib Sensitive : C1
BCR-ABL1 fusion	Leukemia	BCR-ABL1 fusion	Leukemia	asciminib Sensitive: C1 - Off-label asciminib Sensitive : C1	asciminib Sensitive: C1 - Off-label asciminib Sensitive : C1
BCR-ABL1 mutation	Chronic Myeloid Leukemia	BCR-ABL1 mutation	Chronic Myeloid Leukemia	asciminib Sensitive: C2 – Inclusion Criteria asciminib Sensitive : C2	asciminib Sensitive: C2 – Inclusion Criteria asciminib Sensitive : C2
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	dasatinib + asciminib Sensitive: C3 – Early Trials dasatinib + asciminib Sensitive : C3	dasatinib + asciminib Sensitive: C3 – Early Trials dasatinib + asciminib Sensitive : C3
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	nilotinib + asciminib Sensitive: C3 – Early Trials nilotinib + asciminib Sensitive : C3	nilotinib + asciminib Sensitive: C3 – Early Trials nilotinib + asciminib Sensitive : C3
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	imatinib + asciminib Sensitive: C3 – Early Trials imatinib + asciminib Sensitive : C3	imatinib + asciminib Sensitive: C3 – Early Trials imatinib + asciminib Sensitive : C3
BCR-ABL1 T315I	Leukemia	BCR-ABL1 T315I	Leukemia	ponatinib + asciminib Sensitive: D – Preclinical ponatinib + asciminib Sensitive : D	ponatinib + asciminib Sensitive: D – Preclinical ponatinib + asciminib Sensitive : D
BCR-ABL1 F359	Leukemia	BCR-ABL1 F359	Leukemia	ponatinib + asciminib Resistant: D – Preclinical ponatinib + asciminib Resistant : D	ponatinib + asciminib Resistant: D – Preclinical ponatinib + asciminib Resistant : D
NUP214-ABL1 fusion	Acute Lymphocytic Leukemia	NUP214-ABL1 fusion	Acute Lymphocytic Leukemia	asciminib Sensitive: D – Preclinical asciminib Sensitive : D	asciminib Sensitive: D – Preclinical asciminib Sensitive : D
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	axitinib + asciminib Sensitive: D – Preclinical axitinib + asciminib Sensitive : D	axitinib + asciminib Sensitive: D – Preclinical axitinib + asciminib Sensitive : D